(Total Views: 872)
Posted On: 05/07/2025 8:29:43 PM
Post# of 154581
There seems to be a couple of mistakes in that abstract. If mOS for Trodelvy was 11.8 months and overall survival was 25% at 1 year that means 25% of the patient population would have died in the 2 months between the 11.8 months and 1 year. The actual data for real world overall survival is 1 year - 46.8% (125/267) and 2 year - 9.3% (25/267). They also have a listing for the 30 month data - .7% (2/267).
The 30 month comparison is the closest long-term data we have to compare to our 4 year data. So that's .7% vs. 17.8%. In other words leronlimab is at least 25 times better very long term.
https://ascopubs.org/doi/10.1200/JCO.23.01409
The 30 month comparison is the closest long-term data we have to compare to our 4 year data. So that's .7% vs. 17.8%. In other words leronlimab is at least 25 times better very long term.
https://ascopubs.org/doi/10.1200/JCO.23.01409
Quote:
sacituzumab govitecan (ASCENT) (mOS=∼11.8 months, 1 year ∼25%, 2 years 20%).
Pooled analysis of the 3 studies showed from time of leronlimab treatment; mOS 6.8 months (95% CI: 4.4-17.7), survival at 1 yr. 41.3% (95% CI 22.7-59., 2 yr. 24.8% (95% CI:8.0-41.5), and 3 yr. 19.8% (95% CI: 3.8-35.8%). 4 patients who are currently alive without evidence of disease after 42, 48, 49, and 52, months, each had 4 prior lines of systemic therapy and were treated with leronlimab either in combination or subsequently, with checkpoint inhibitors: pembrolizumab (N=1) or atezolizumab (N=3) and chemotherapy (N=4).
(24)
(0)
